Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
33°
Sunny
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
174.89
-1.28 (-0.73%)
Streaming Delayed Price
Updated: 2:48 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
71
72
Next >
Navigating 14 Analyst Ratings For AbbVie
November 12, 2024
Via
Benzinga
Biotech Stocks Are Rallying: What Is Your Playbook?
November 11, 2024
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers.
Via
Talk Markets
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 11, 2024
Via
Benzinga
Why AbbVie Stock Was Getting Mashed on Monday
November 11, 2024
A splashy recent acquisition by the company might not be panning out.
Via
The Motley Fool
AbbVie Stock Drops 12% On Schizophrenia Drug Setback: Should You Buy The Dip?
November 11, 2024
AbbVie reports disappointing mid-stage data for its schizophrenia drug.
Via
Talk Markets
What's Going On With Bristol-Myers Squibb Shares Monday?
November 11, 2024
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc (NYSE:ABBV) announced that its Phase 2 EMPOWER trials did not meet...
Via
Benzinga
This Is What Whales Are Betting On AbbVie
November 11, 2024
Via
Benzinga
My Favorite Dividend King to Buy in November
November 09, 2024
This Dividend King truly wears the crown.
Via
The Motley Fool
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
November 11, 2024
AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company's broader drug pipeline.
Via
Benzinga
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
November 11, 2024
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for next steps.
Via
Benzinga
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
November 11, 2024
AbbVie stock also tumbled after its experimental schizophrenia treatment failed in two Phase 2 studies.
Via
Investor's Business Daily
3 Spectacular High-Yield Dividend Stocks to Buy in November
November 10, 2024
High yields aren't a warning indicator with these three stocks.
Via
The Motley Fool
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
November 08, 2024
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and...
Via
Benzinga
What the Options Market Tells Us About AbbVie
November 06, 2024
Via
Benzinga
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
November 04, 2024
Via
Benzinga
AbbVie Dividend Increase
November 03, 2024
On 30 October, AbbVie (ABBV) increased its quarterly dividend by 5.81%, from $1.55 to $1.64 per share.
Via
Talk Markets
2 Dividend Kings That Would Have Doubled Your Money in 5 Years
November 08, 2024
You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.
Via
The Motley Fool
Dividend Watch: Three Companies Boosting Quarterly Payouts
November 07, 2024
Everybody loves dividends, as they provide a passive income stream. Recently, three companies have announced payout increases. Let’s take a closer look at each.
Via
Talk Markets
Is Eli Lilly a Buy? Analyst Confidence Grows for 2025
November 05, 2024
Eli Lilly's price pullback is an opportunity worth 25%, with analysts' sentiment firming around the $1000 level. New highs are likely by early 2025.
Via
MarketBeat
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
November 05, 2024
After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight
November 04, 2024
High-yielding AbbVie is on track for another 20% gain, which could happen by the end of the year. Analysts are raising their targets, leading to higher prices.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Price Over Earnings Overview: AbbVie
November 01, 2024
Via
Benzinga
Market Analysis: AbbVie And Competitors In Biotechnology Industry
October 31, 2024
Via
Benzinga
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
November 01, 2024
On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79.
Via
Investor's Business Daily
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
November 01, 2024
The major indexes declined, but haven't fallen apart.
Via
Investor's Business Daily
5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs
October 31, 2024
It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly.
Via
The Motley Fool
AbbVie’s Dividend Isn’t As Scary As It Looks
October 30, 2024
AbbVie currently pays shareholders a quarterly dividend of $1.55 per share, which gives the stock a 3.3% yield on the current price.
Via
Talk Markets
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via
Benzinga
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
October 30, 2024
Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data.
Via
Benzinga
AbbVie (ABBV) Q3 2024 Earnings Call Transcript
October 30, 2024
ABBV earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
6
7
8
9
...
71
72
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.